x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012195
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Isotype | IgG |
| Host Species | Rabbit |
| Reactivity | Mouse |
| Applications | WB, IP |
| Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala105 of mouse IRGM protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | Irgm1 |
| UniProt No. | Q60766 |
| Gene ID | 15944 |
| Gene Description | Immunity-related GTPase family M protein 1 belongs to the p47 family of immunity related guanosine triphosphatases that regulate innate immune responses to intracellular pathogens. Research studies indicate that IRGM plays a role in autophagy during clearance of intracellular bacteria. Expression of IRGM in mice, but not in humans, is induced by inflammatory signals that include interferon and LPS. Polymorphisms in the corresponding IRGM gene are associated with some cases of tuberculosis, Crohn’s disease, and severe sepsis. Additional studies indicate that IRGM functions through regulation of autophagy. Mitochondrial IRGM plays a role in mitochondrial fission, membrane polarization, and mitophagy. Knockout mice for IRGM show increased susceptibility to infection as well as intestinal inflammation and Paneth cell abnormalities. Knockout mice against IRGM are also resistant to neuronal autophagy following stroke. RNA viruses commonly target IRGM in order to suppress autophagy and enhance infection. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
